Essential Partners’s CorMedix CRMD Stock Holding History

Essential Partners’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-3	Closed	-$37	–	2694
2025 Q2	$37	Buy	+3	New	+$33	﹤0.01%	2175

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Essential Partners's CRMD Position: Q3 2025 in Review

Essential Partners sold out of CorMedix (CRMD) in Q3 2025, closing a stake of 3 shares — an estimated $37 sold.

Essential Partners first reported a position in CRMD in Q2 2025 and held it in 1 quarter. The position peaked at $37 in Q2 2025. 190 funds tracked by Wall St. Rank hold CRMD as of Q3 2025.

Essential Partners reported no remaining CorMedix position as of Q3 2025 after selling out during the quarter.
Essential Partners sold 3 CorMedix shares in Q3 2025, an estimated $37.
Essential Partners first reported a position in CorMedix in Q2 2025 and held it in 1 quarter.
Essential Partners's CorMedix position peaked at $37 in Q2 2025.
190 funds tracked by Wall St. Rank held CorMedix as of Q3 2025.

Based on Essential Partners's 13F filing for Q3 2025, filed 21 May 2026.